AMLX · Amylyx Pharmaceuticals, Inc.
$37.08
-0.38 (-1.01%)
At close · Aug 26
Market Cap
$4.29B
Shares
111.42M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$144.74M
+52%
FY2025
Gross Margin
93.19%
-0.1pp
FY2024
Operating Margin
-360.22%
-370.4pp
FY2024
Diluted EPS
-$1.53
+65.5%
FY2025
Operating Cash Flow
-$123.34M
+26.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | $0 | $87.37M | $380.79M | $22.23M | $285K | |
| — | $0 | $5.95M | $25.44M | $2.99M | — | |
| — | $0 | $81.42M | $355.35M | $19.24M | — | |
| — | — | 93.19% | 93.32% | 86.54% | — | |
| $92.45M | $90.4M | $104.08M | $128.19M | $93.45M | $44.04M | |
| $69.66M | $62.89M | $114.33M | $188.36M | $127.13M | $38.93M | |
| — | $0 | $22.85M | — | — | — | |
| $162.1M | $153.29M | $402.1M | $341.98M | $223.57M | $82.97M | |
| -$162.1M | -$153.29M | -$314.73M | $38.8M | -$201.34M | -$82.69M | |
| — | — | -360.22% | 10.19% | -905.72% | -29013.33% | |
| $10M | $9.3M | $13.81M | $16.16M | $4.29M | $36K | |
| $10.06M | $8.6M | $12.6M | $15.5M | $3.74M | -$5.24M | |
| — | -$144.69M | -$302.14M | $54.3M | -$197.6M | -$87.93M | |
| — | $46K | -$393K | $5.03M | $774K | — | |
| -$152.09M | -$144.74M | -$301.74M | $49.27M | -$198.38M | -$87.93M | |
| — | — | -345.36% | 12.94% | -892.38% | -30852.98% | |
| -$152.62M | -$144.24M | -$302.03M | $49.55M | -$198.47M | -$87.92M | |
| USD/shares | — | -$1.53 | -$4.43 | $0.73 | -$3.39 | -$13.35 |
| USD/shares | — | -$1.53 | -$4.43 | $0.70 | -$3.39 | -$13.35 |
| shares | — | 94.57M | 68.14M | 67.23M | 58.5M | 6.59M |
| shares | — | 94.57M | 68.14M | 69.99M | 58.5M | 6.59M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.60×
EV/EBIT
—
Peer median 17.89×
P/E (TTM)
—
Peer median 18.47×
Peer medians compare against the 39 similar-size Drug Manufacturers - Specialty & Generic companies (of 102 listed).
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1658551
CUSIP
03237H101
13F (30d)
188 filings
188 filers
Visit website
Investor relations